Effect of the neridronate on RANKL release in differentiated primary human osteoblasts
Submitted: 29 November 2010
Accepted: 7 March 2011
Published: 29 March 2011
Accepted: 7 March 2011
Abstract Views: 833
PDF: 447
HTML: 1295
HTML: 1295
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Supporting Agencies
Nicolin, V., Valentini, R., Bortul, R., & Fancellu, G. (2011). Effect of the neridronate on RANKL release in differentiated primary human osteoblasts. Drugs and Therapy Studies, 1(1), e3. https://doi.org/10.4081/dts.2011.e3
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.